Core Viewpoint - OSE Immunotherapeutics presents its innovative OSE-Cytomask® technology at the SITC 2025 Annual Meeting, which aims to enhance the therapeutic index of immunocytokines by enabling targeted cytokine activation in tumor-specific T cell populations [1][4]. Technology Overview - OSE-Cytomask® is a proprietary non-cleavable linker technology that allows for the creation of a new class of regulated and targeted cytokine therapeutics, addressing unmet needs in immunocytokine therapy [2][5]. - The technology keeps cytokines inactive until they reach the appropriate immune cells, specifically those expressing PD-1, thus minimizing unwanted activation in healthy tissues and reducing side effects [3][5]. Research and Development - The technology has been successfully tested with various antibodies and cytokines, including IL-15, IL-2, and IL-10, indicating its potential to enhance existing therapies and improve safety and effectiveness for patients with hard-to-treat solid tumors [5]. Company Background - OSE Immunotherapeutics is focused on developing first-in-class assets in immuno-oncology and immuno-inflammation, partnering with leading academic institutions and biopharmaceutical companies to bring transformative medicines to market [6].